Biocartis Group (LSE:0R72) - Hisse Senedi Fiyatı, Haberler ve Analizler

0R72 Stoklara Genel Bakış

A molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Daha fazla detay

0R72 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Gelirin yılda 22.28% oranında artması öngörülüyor

Risk Analizi

Kazançlar son 5 yılda yılda 7.1% oranında azaldı

1 yıldan az nakit akışı var

Negatif hissedar öz sermayesi

Hisse senetleri oldukça likit değildir

+ 2 daha fazla risk

Biocartis Group NV Rakipler

Ondine Biomedical

AIM:OBI

UK£22.9m

Polarean Imaging

AIM:POLX

UK£18.7m

Inspiration Healthcare Group

AIM:IHC

UK£14.1m

ANGLE

AIM:AGL

UK£33.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Biocartis Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€0.30
52 Haftanın En Yüksek Seviyesi	€0.76
52 Haftanın En Düşük Seviyesi	€0.30
Beta	1.38
11 Aylık Değişim	0%
3 Aylık Değişim	4.00%
1 Yıllık Değişim	-43.90%
33 Yıllık Değişim	-93.57%
5 Yıllık Değişim	-97.01%
Halka arzdan bu yana değişim	-97.88%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0R72	GB Medical Equipment	GB Pazar
7D	0%	-0.2%	1.7%
1Y	-43.9%	-2.3%	8.3%

Getiri vs. Endüstri: 0R72 geçen yıl % -2.3 oranında getiri sağlayan UK Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: 0R72 geçen yıl % 8.3 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0R72's price volatile compared to industry and market?
0R72 volatility
0R72 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0R72 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 0R72 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	526	Roger Moody	www.biocartisgroupnv.be

Biocartis Group NV Temel Bilgiler Özeti

Biocartis Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0R72 temel i̇stati̇sti̇kler
Piyasa değeri	€27.24m
Kazançlar(TTM)	-€67.87m
Gelir(TTM)	€60.82m

0.4x

P/S Oranı

-0.4x

F/K Oranı

0R72 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0R72 gelir tablosu (TTM)
Gelir	€60.82m
Gelir Maliyeti	€65.51m
Brüt Kâr	-€4.69m
Diğer Giderler	€63.18m
Kazançlar	-€67.87m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.72
Brüt Marj	-7.71%
Net Kâr Marjı	-111.58%
Borç/Özkaynak Oranı	-257.9%

0R72 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0R72 Stoklara Genel Bakış

Ödüller

Risk Analizi

Biocartis Group NV Rakipler

AIM:OBI

UK£22.9m

AIM:POLX

UK£18.7m

AIM:IHC

UK£14.1m

AIM:AGL

UK£33.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

New minor risk - Share price stability

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings released: €1.24 loss per share (vs €1.11 loss in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.38

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

Revenue beats expectations

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

New 90-day low: €4.15

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

New 90-day high - €5.03

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Biocartis Group NV Temel Bilgiler Özeti

0.4x

-0.4x

Kazanç ve Gelir